GlaxoSmithKline's MAGE-A3 cancer vaccine was viewed as a long shot by some analysts even before it missed its first co-primary endpoint last year. Yet while analysts lowered expectations in the wake of the weak data in melanoma patients, GSK is continuing to promote its prospects.
GlaxoSmithKline confidently claimed a leading role for new drug development in the Big Pharma world on Wednesday, citing a rising return on its multibillion-dollar R&D budget while looking to swell its late-stage pipeline in 2014 and 2015 with about 10 new therapies.
GlaxoSmithKline released its 2013 earnings report today, and made it abundantly clear that five new drug approvals in 2013 helped cushion the impact of increasing competition on older products and a bribery scandal in China.
Advair's throne is slowly eroding. With stepped-up competition from rival lung drugs--including AstraZeneca's Symbicort--GlaxoSmithKline's top-selling product, with $7.7 billion in 2012 sales, is losing share in the U.S.
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
When the Centers for Disease Control and Prevention looked into the reasons behind low uptake of GlaxoSmithKline's and Merck's human papillomavirus vaccines last year, the effect of parental attitudes to sex grabbed the headlines. Yet while parents may fear the vaccine will lead to risky sex, all the evidence suggests otherwise.
The U.S. childhood immunization schedule is overwhelmingly made up of injectables. Yet in among the vaccines for measles, mumps and other diseases are two orally delivered products--GlaxoSmithKline's and Merck's rotavirus vaccines. The rarity of oral vaccines means providers have less experience delivering them, but does this mean there are more errors?
GlaxoSmithKline picked up a slate of new drug approvals in 2013, a key accomplishment for a pharma giant that set out several years ago to shake up a moribund, multibillion-dollar research operation.
It turns out that Germany will not be the only country facing a shortage of GlaxoSmithKline's chickenpox vaccines. While healthcare providers there have already been given a heads up to prepare for rationing, the company says deliveries worldwide will be affected.
GlaxoSmithKline is inching toward European approval for albiglutide, winning a recommendation for its latest diabetes contender as the market for similar drugs gets more and more crowded.